In this article, we will discuss 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts.
Penny stocks remain one of the most controversial corners of the market — capable of producing enormous gains, devastating losses, and endless debate among billionaire investors and hedge fund managers. While some legendary investors see penny stocks as dangerous speculation filled with manipulation and hype, others acknowledge that overlooked small-cap companies can occasionally become extraordinary multibaggers.
Investors inspired by Peter Lynch continue searching for overlooked small-cap companies before Wall Street discovers them. Lynch famously argued that individual investors can sometimes identify opportunities that institutional investors miss, particularly in smaller or lesser-known businesses. His Magellan Fund reportedly generated an annualized return of roughly 29.2% over 13 years, making him one of the greatest growth investors in history.
At the same time, hedge fund managers such as David Einhorn and Michael Burry have also repeatedly warned investors about speculative excess in highly volatile market segments. Einhorn recently warned that speculative retail behavior resembles prior bubble periods and argued that many overvalued stocks could eventually collapse when fundamentals fail to justify expectations.
Recent academic studies show why penny stocks continue attracting investors despite the risks. Research published on arXiv analyzing 167 penny stocks listed on India’s National Stock Exchange found that lower market-cap penny stocks significantly outperformed larger penny stocks, while lower P/E and lower price-to-book penny stocks also generated higher returns. Another major study published in the Journal of Banking & Finance found that roughly 30% of highly shorted stocks also had high hedge-fund ownership, demonstrating the enormous disagreement and speculative behavior often surrounding risky equities.
The appeal of penny stocks lies in their explosive upside potential. Investors are drawn to the possibility of discovering small companies before they achieve mainstream success, especially in emerging industries like biotechnology, AI, mining, clean energy, and fintech. However, penny stocks also carry some of the market’s highest risks, including poor liquidity, weak financials, and volatility.
With this context in mind, here are some of the best-rated penny stocks to buy according to Wall Street analysts.
Our Methodology
We used stock screeners to identify a list of penny stocks with upside potential of over 30%. We limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds. To make the list easier to navigate, we ranked the stocks in ascending order of their upside potential.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
7 Best Rated Penny Stocks to Buy According to Wall Street Analysts
7. Embecta Corp. (NASDAQ:EMBC)
Upside Potential: 32.01%
On May 18, Bank of America analyst Travis Steed lowered the firm’s price target on Embecta Corp. (NASDAQ:EMBC) to $3 from $11 while maintaining an Underperform rating on the shares. Following meetings with 34 medtech companies in Las Vegas, the analyst updated multiple healthcare valuation models to reflect what the firm described as a “new reality” for medtech stocks. Bank of America cited concerns surrounding a lack of major product cycles, the Affordable Care Act, and utilization-related uncertainties, inflationary pressures following geopolitical instability, and investor preference shifting toward artificial intelligence and data center investments rather than healthcare equities. The revised target reflects broader sector-wide caution despite Embecta’s established presence in diabetes care solutions.
Earlier, on May 6, Mizuho Financial Group lowered its price target on Embecta Corp. to $5 from $12 while maintaining a Neutral rating. The adjustment came amid continued pressure across the broader medical technology sector, where analysts remain cautious regarding reimbursement trends, healthcare utilization patterns, and the pace of innovation-driven growth. Despite the lowered valuation targets, Embecta continues to maintain a significant position within the global diabetes care market through its specialized insulin delivery product portfolio.
Founded in 2022 and headquartered in Parsippany, Embecta Corp. is a global medical technology company focused exclusively on diabetes care solutions. The company specializes in insulin delivery systems, including syringes and pen needles, while also investing in digital health technologies aimed at improving diabetes management and patient outcomes.
6. eHealth, Inc. (NASDAQ:EHTH)
Upside Potential: 39.66%
On May 8, Deutsche Bank analyst George Hill raised the firm’s price target on eHealth, Inc. (NASDAQ:EHTH) to $3 from $2 while maintaining a Hold rating on the shares. The revised target reflects improving operational execution and stronger financial momentum following the company’s recent quarterly performance. Analysts continue to monitor the company’s ability to expand enrollment volumes, improve customer acquisition efficiency, and strengthen profitability within the competitive online health insurance marketplace industry.
On May 6, eHealth, Inc. reported first-quarter revenue of $88 million, exceeding consensus estimates of $81.27 million. Chief Executive Officer Derrick Duke stated that the stronger-than-expected results were driven by higher enrollment volume and favorable acquisition costs during the quarter. Management also highlighted meaningful progress toward fiscal 2026 strategic initiatives, including targeted cost reductions and readiness work supporting newly launched programs. Among the company’s major initiatives were the rollout of its lifetime advisory model and the introduction of a new final expense insurance product, both aimed at strengthening eHealth’s ability to help consumers navigate increasingly complex healthcare and insurance decisions.
Founded in 1997 and headquartered in Santa Clara, eHealth, Inc. operates a leading private online marketplace for health insurance products. The company enables individuals, families, and small businesses to digitally compare, research, and enroll in health insurance plans across a broad range of providers and coverage categories.
5. Alight, Inc. (NYSE:ALIT)
Upside Potential: 58.75%
On May 13, Alight, Inc. (NYSE:ALIT) announced the expansion of its Alight Partner Network through the addition of Cylinder Health and Leap. The company stated that the additions strengthen Alight’s ability to help employers deliver high-impact health and employee engagement solutions through an integrated ecosystem of workplace services. The Alight Partner Network is designed to provide employers with curated healthcare, benefits, and wellness offerings that improve employee engagement and streamline access to specialized solutions through existing Alight client relationships. Management believes the expanded network will enhance the company’s ability to provide more connected and personalized employee experiences.
Earlier, on May 1, Alight, Inc. announced two executive leadership appointments aimed at supporting operational execution and long-term growth initiatives. Dinesh Tulsiani was appointed President of Employer Solutions effective May 1, 2026, while Susan Davies, previously the company’s Chief Accounting Officer and Global Controller, was named Interim Chief Financial Officer effective May 8, 2026, following the previously announced departure of Greg Giometti. The leadership changes reflect Alight’s continued emphasis on operational excellence, innovation, and strategic expansion across its cloud-based HR and employee benefits platform.
Founded in 2017 and headquartered in Chicago, Alight, Inc. is a cloud-based provider of human resources, payroll, employee engagement, and financial wellness technology solutions for large organizations.
4. Prairie Operating Co. (NASDAQ:PROP)
Upside Potential: 329.07%
On May 15, Roth Capital lowered its price target on Prairie Operating Co. (NASDAQ:PROP) to $3.50 from $4 while maintaining a Buy rating following the company’s first-quarter report. The firm reduced its 2026 cash flow per share estimates by approximately 20%, citing weaker first-quarter performance, an increased share count, and hedge positions that were below the firm’s commodity price assumptions. Despite the downward revision, Roth Capital maintained a constructive view on the shares, suggesting that the company still offers attractive long-term upside potential relative to current valuation levels.
Previously, on April 10, Roth Capital analyst Leo Mariani characterized the sharp selloff in Prairie Operating Co. shares following the restructuring of its preferred stock agreement as a buying opportunity. The company reached an agreement with preferred shareholder Hudson Bay to reduce anniversary warrant coverage from 125% to 75% of stated value, lowering potential dilution from approximately 77 million shares to 34 million shares while extending the warrant issuance deadline to July 8, 2026. In exchange, Hudson Bay received immediate penny warrants covering 4 million shares, with an additional 3 million-share warrant contingent upon future issuance conditions. Although Roth reduced earnings estimates due to the higher share count, the firm expressed surprise at the severity of the market reaction and reiterated its Buy rating.
Founded in 2023 and headquartered in Houston, Prairie Operating Co. is an independent energy company focused on the acquisition, development, and production of crude oil, natural gas, and natural gas liquids. Its core operations are concentrated within the Denver-Julesburg Basin in Weld County, Colorado.
3. Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)
Upside Potential: 843.40%
On May 18, H.C. Wainwright analyst Swayampakula Ramakanth assumed coverage of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) with a Buy rating and a $4 price target. According to the analyst, the company’s lead therapy, LYMPHIR, has already received approval for the treatment of relapsed or refractory Stage I-III cutaneous T-cell lymphoma. H.C. Wainwright noted that early commercial launch metrics appear encouraging, highlighting nearly full commercial insurance coverage, strong formulary positioning across target healthcare accounts, and the company’s initial international shipment into Europe through a regional distribution partner. The firm believes these developments support the broader commercialization outlook for LYMPHIR as Citius continues expanding market access.
Previously, on April 29, Citius Oncology, the majority-owned subsidiary of Citius Pharmaceuticals, Inc., announced the first shipment of LYMPHIR into Europe through one of its regional distribution partners. The therapy will initially be provided to eligible patients through Named Patient Programs in accordance with local country regulations. Management described the European launch initiative as an important strategic milestone in expanding international access for patients with limited treatment options while maintaining a disciplined commercial rollout strategy. LYMPHIR previously received approval from the U.S. Food and Drug Administration in August 2024 for adult patients with relapsed or refractory cutaneous T-cell lymphoma following at least one prior systemic therapy and was commercially launched in the United States in December 2025.
Founded in 2007 and headquartered in Cranford, Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing critical care and oncology therapies. The company’s pipeline includes treatments targeting unmet medical needs in oncology, infectious disease management, and supportive care markets.
2. NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)
Upside Potential: 1194.87%
On May 13, Lucid Capital initiated coverage of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) with a Buy rating and a $49 price target. The firm stated that NRx is preparing to enter the approximately $1.5 billion North American ketamine market through both a proprietary generic product and a branded formulation. According to the analyst, the company has developed a preservative-free ketamine formulation with a potential shelf life of up to three years, which could represent a meaningful competitive advantage within the market. Lucid Capital believes the company’s differentiated formulation and manufacturing capabilities position it favorably as demand grows for mental health and central nervous system therapies.
Earlier, on May 5, NRx Pharmaceuticals, Inc. announced the initiation of its first commercial manufacturing order for its preservative-free ketamine product ahead of an anticipated approval expected during the summer of 2026. Chairman and Chief Executive Officer Jonathan Javitt stated that the company looks forward to delivering a safe and convenient U.S.-manufactured ketamine product to the market. Management noted that the manufacturing order follows stability data from multiple registration batches and a successful third-party audit of the manufacturing facility. The company also emphasized that its blow-fill-seal manufacturing process enables production throughput more than ten times greater than traditional sterile bottling methods while supporting rapid future scalability as demand increases.
Founded in 2015 and headquartered in Wilmington, NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies targeting central nervous system disorders, including severe suicidal depression, post-traumatic stress disorder, and bipolar depression.
1. VolitionRx Limited (NYSEAMERICAN:VNRX)
Upside Potential: 1451.32%
On May 15, Cameron Reynolds, President and Group Chief Executive Officer of VolitionRx Limited (NYSEAMERICAN:VNRX), stated that the company made substantial progress across multiple product platforms during the first quarter and following quarter-end developments. Management highlighted the submission for peer review of a clinical manuscript demonstrating high accuracy for the company’s Nu.Q Vet feline prototype assay in detecting lymphoma in cats, representing the third animal species supported by the platform. VolitionRx noted that publication of the study in a peer-reviewed journal is expected to trigger a $5 million contractual milestone payment. The company also believes the feline assay could significantly expand the commercial opportunity for its Nu.Q Vet diagnostic platform within veterinary healthcare markets.
Previously, on April 29, VolitionRx Limited announced a major technical milestone involving the successful detection of nucleosomes in capillary blood samples collected from critically ill sepsis patients using the company’s lateral flow prototype technology. The finger-prick testing platform is designed for potential bedside, emergency room, or at-home diagnostic use, similar to rapid COVID-19 or pregnancy tests. Management stated that the study, conducted as part of the SUMMIT program, demonstrated the feasibility of rapidly detecting immune disruptions associated with conditions such as sepsis without requiring centralized laboratory analysis. The advancement could substantially broaden the market opportunity for VolitionRx’s diagnostic technologies beyond traditional clinical laboratory settings.
Founded in 1998 and headquartered in Henderson, VolitionRx Limited is a multinational epigenetics company focused on developing cost-effective blood tests for early cancer detection and immune monitoring in both humans and animals. The company’s proprietary technologies analyze nucleosomes circulating in the bloodstream to help identify and monitor serious diseases and health conditions.
